

COVID 19: An SEIR model predicting disease progression and healthcare outcomes for

Pakistan

Ejaz Ahmad Khan^{1*}, Maida Umar², Maryam Khalid³

^{1*}Associate Professor, Health Services Academy, Islamabad, Pakistan

²Data Analyst, United Nations Development Programme, Pakistan

³Lecturer, Quaid-i-Azam University, Islamabad, Pakistan.

*Corresponding author: ejaz@hsa.edu.pk (EAK)

Abstract

Background: Recent pandemic of the Noval Coronal Virus (COVID 19) has claimed more than 200,000 lives and about 3.8 million infected worldwide. Countries are being gradually exposed to its devastating threat without being properly prepared and with inadequate response. COVID 19's first two cases were reported in Pakistan on February 26, 2020. We present a model depicting progression of epidemiology curve for Pakistan with and without interventions in view of its health system' response capacity in near future.

Methodology: We used a modified compartmental epidemiological SEIR model to describe the outbreak of COVID-19 in Pakistan including the possibility of asymptomatic infection and presymptomatic transmission. The behavior of the dynamic model is determined by a set of clinical parameters and transmission rate.

Results: We estimated that in the absence of a set of proven interventions, the total susceptible population would be 43.24 million, exposed individuals would be almost 32 million, asymptomatic cases would be 13.13 million, mildly infected 30.64 million, severely infected slightly more than 6 million and critical cases would be around 967,000 in number. By that time, almost 760,000 fatalities of infected critical would have taken place. Comparing with the healthcare capacity of Pakistan, if we could "flatten the curve" to a level below the dashed grey line, the healthcare system will be capable of managing the cases with ideal healthcare facilities,

26 where the grey line representing the healthcare capacity of Pakistan. With the intervention in
27 place, the number of symptomatic infected individuals is expected to be almost 20 million.

28 **Conclusion:** We consider the impact of intervention and control measures on the spread of
29 COVID-19 with 30% reduction in transmission from mild cases in case a set of interventions are
30 judiciously in place to mitigate its impact.

31 **Keywords:** Pandemic, novel corona virus, trend of diseases outbreak, modeling, low middle
32 income country

33 **Background**

34 December 2019 witnessed a new challenge to the advances of Public Health when a novel
35 corona virus emerged on the face of Earth infecting China's Wuhan province and spread along
36 219 countries of the World within next four months causing more than four million cases and
37 nearly a quarter of million deaths, mostly in Europe and United States. The COVID 19, as the
38 name given to it, has been identified having three main strains: A, B and C. The 'B' strain
39 inflicted Chinese population and mutated to type 'C' when it reached Europe after clustering in
40 Singapore(1,2). It also reached Iran and from there to Pakistan. Pakistan had its first report of
41 cases on February 26th, 2020(3). Since then, by 16th of May, there have been reported 38,799
42 cases, with 834 deaths and 10,880 recovered cases(4).

43 A pandemic need to be understood in the context of its epidemiology and expected number of
44 cases with its case fatality rate and health system's capacity in dealing with the critical patient
45 load with respect to its surge capacity, in an absence of proper preparedness. We conducted this
46 analysis, based on estimates considering that the cases identified were not the true picture due to
47 insufficient testing capacity and an absence of R_0 for the country, to model Pakistan's COVID
48 19's trends and the health system's capacity in dealing with the pandemic. This paper intends to
49 assess the effects of interventions like lock down, social distancing and awareness campaigns in
50 Pakistan via means of reduction in transmission. In the absence of any pharmaceutical aid, the
51 only interventions that can be implemented to avoid the spread of COVID-19 are social
52 distancing, self-quarantine and use of protective gears. The first lockdown was officially
53 imposed on 24th March, 2020 by the government in Pakistan and then eventually moved towards
54 a soft lockdown(4).

55 **Methods**

56 A modified compartmental epidemiological SEIR model is used to describe the outbreak of
57 COVID-19 in Pakistan including the possibility of asymptomatic infection and presymptomatic
58 transmission. The behavior of the dynamic model is determined by a set of clinical parameters
59 and transmission rate(5,6).The classic SEIR model assumes that an individual in the population
60 is susceptible (S), exposed (E) where they are asymptomatic and do not transmit infection,
61 infected and infectious (I), or recovered and immune (R) (7,8). It is assumed that when an
62 individual is symptomatic and infected, the progression from exposed stage (E) to becoming
63 infected and infectious (I) occur at the rate α . The model considers three clinical stages of
64 infections: mild, severe and critical (9) (refer to as I_1, I_2, I_3 onwards) (10). Each infection stage
65 of an individual has two possible outcomes: recovery and progression towards next stage leading
66 to death. Let $\gamma_1, \gamma_2, \gamma_3$ be the recovery rates at each of the three infectious stages respectively
67 and let ρ_1, ρ_2 be the progression rates from I_1 to I_2 and from I_2 to I_3 respectively. While let δ
68 be the transition rate of the death (D) an individual at I_3 . Let $\theta_1, \theta_2, \theta_3$ be the respective
69 transmission rates at the three stages I_1, I_2, I_3 of the model.

$$S' = -(\theta_1 I_1 + \theta_2 I_2 + \theta_3 I_3)S \quad (1)$$

$$E' = (\theta_1 I_1 + \theta_2 I_2 + \theta_3 I_3)S - \alpha E \quad (2)$$

$$I_1' = \alpha E - (\gamma_1 + \rho_1)I_1 \quad (3)$$

$$I_2' = \rho_1 I_1 - (\gamma_2 + \rho_2)I_2 \quad (4)$$

$$I_3' = \rho_2 I_2 - (\gamma_3 + \delta)I_3 \quad (5)$$

$$R' = \gamma_1 I_1 + \gamma_2 I_2 + \gamma_3 I_3 \quad (6)$$

$$D' = \delta I_3 \quad (7)$$

$$N = S + E + I_1 + I_2 + I_3 + R + D$$

70 where

71 θ_i = the rate at which the infected individual in class I_i contact susceptibles and infect them

72 α = the rate of progression from exposed to infected

73 γ_i = the rate at which the infected individual in class I_i recover from the disease

74 ρ_i = the rate at which the infected individual in class I_i progress to the next class I_{i+1}

75 δ = the death rate of individuals in most severe stage of infection.

76 S : Susceptible Individuals

77 E : Exposed Individuals (Infected but asymptomatic)

78 I_i : Infected Individuals in class i for $i = 1, 2, 3$

79 R : Individuals Recovered and are now immune

80 D : Individuals died of infection

81 N : Total population

82 The parameters of the model define above are then estimated as follows, incorporating the
83 information from clinical data.

84

$$\alpha = \frac{1}{\beta}$$

β : Average incubation period in days

$$\gamma_1 = \frac{FI_M}{DI_M}$$

FI_M : Average fraction of mild symptomatic infections

$$\rho_1 = \frac{1}{DI_M} - \gamma_1$$

DI_M : Average duration of mild infections in days

$$\rho_2 = \frac{FI_C}{FI_S + FI_C} \left(\frac{1}{\eta} \right)$$

FI_S : Average fraction of severe symptomatic infections

FI_C : Average fraction of critical symptomatic infections

$$\gamma_2 = \frac{1}{\eta} - \rho_2$$

η : Average duration of hospitalization for individuals
with severe infection in days

$$\delta = \frac{CFR}{FI_C} \left(\frac{1}{\lambda} \right)$$

CFR: Case fatality rate

$$\gamma_3 = \frac{1}{\lambda} - \delta$$

λ : Average duration of ICU admission until death in days

85

86 Let r be the exponential growth rate for the epidemic, at initial stage, with the doubling time

87 $T_2 = \frac{\ln(2)}{r}$. The ratio of individuals during the initial stage of any epidemic is fixed between any

88 two compartments and their expected values can be computed using the underlying model with

89 fixed parameters. The expected ratios are given as follows:

$$\frac{I_3}{D} = \frac{r}{\delta}$$

$$\frac{I_2}{D} = \frac{(r + \delta + \gamma_3)}{\rho_2} \left(\frac{r}{\delta} \right)$$

$$\frac{I_1}{D} = \left(\frac{r + \rho_2 + \gamma_2}{\rho_1} \right) \left(\frac{r + \delta + \gamma_3}{\rho_2} \right) \left(\frac{r}{\delta} \right)$$

$$\frac{I}{D} = \frac{\sum_{i=1}^3 I_i}{D} = \left(1 + \left(\frac{r + \delta + \gamma_3}{\rho_2} \right) \left(1 + \left(\frac{r + \rho_2 + \gamma_2}{\rho_1} \right) \right) \right) \left(\frac{r}{\delta} \right)$$

$$\frac{E}{D} = \left(\frac{r + \rho_1 + \gamma_1}{\alpha} \right) \left(\frac{r + \rho_2 + \gamma_2}{\rho_1} \right) \left(\frac{r + \delta + \gamma_3}{\rho_2} \right) \left(\frac{r}{\delta} \right)$$

90 These expected ratios can further be used to determine the number of under reported cases under
 91 the following assumptions:

- 92 i. The model is formulated as a system of differential equations and its output represents the
 93 expected values of each quantity. Further, as the stochastic events are not considered
 94 therefore it cannot be assumed that the epidemic will extinct even for the very low values
 95 Also, the model does not report the expected variance in the variables, which can
 96 sometimes be large.
- 97 ii. All individuals have equal transmission rates and equal susceptibility to infection.
- 98 iii. Individuals must pass through stage before reaching stage and only the individuals at
 99 critical stage die.

100 The simulation study assumes $N = 220,892,340$ and $Initial\ Infected = 2$ for Pakistan. The
 101 parametric values are either adapted from the literature or from the official statistics (Table 1)
 102 and (Table 2).

103 **Table 1: Estimated parameters for COVID-19 clinical progression**

| Parameter | Value |
|-----------|--------|
| β | 5 days |

| Parameter | Value |
|-------------------------------------|--------------|
| FI_M | 80% |
| FI_S | 15% |
| FI_C | 5% |
| DI_M | 6 days |
| DI_S | 8 days |
| DI_C | 8 days |
| η | 14 days |
| δ | 72% |
| CFR | 2% |
| Time from symptoms to ICU admission | 12 days |
| Time from symptom onset to death | 20 days |
| Serial interval | 8 days |

104 Despite close monitoring, there are chances of asymptomatic COVID-19 infection (11). This
105 paper incorporates the possibility of such infections by assuming that all the individuals
106 progressing from E to I can be categorized as either asymptomatic or symptomatic. Let π be the
107 proportion of individuals with asymptomatic infections such that they progress to I_0 from the
108 stage E, whereas $(1-\pi)$ be the proportion of symptomatic individuals that progress to I_1 from
109 the stage E. Thus the asymptomatic exposed class can be categorized into two sub-classes
110 namely E_0 (no symptoms and no transmission) and E_1 (no symptoms but transmit at the rate θ_E)

111 with the rate of exit being α_0 & α_1 from each sub class respectively. It is pertinent to note that E_1
 112 represents the pre symptomatic class where delayed symptoms are observed relative to when an
 113 individual actually got infected with COVID-19.

114 Assuming that the asymptomatic infections cannot progress to severe stages and have a
 115 transmission rate θ_0 , let γ_0 be the recovery rate of such individuals. Furthermore, all the
 116 transmission rates are modified to incorporate the seasonality factor $\sigma(t) = 1 + \varepsilon \cos(2\pi(t-\varphi))$
 117 where $\varepsilon \in [0,1]$ is the relative amplitude of seasonal oscillation and $\varphi \in [-\infty, \infty]$ is the phase that
 118 determine the peak time (in years) relative to starting time. The customized SEIR model is thus
 119 given as:

$$S' = -(\theta_E E_1 + \theta_1 I_1 + \theta_2 I_2 + \theta_3 I_3)S\sigma(t) \quad (8)$$

$$E' = (\theta_E E_1 + \theta_1 I_1 + \theta_2 I_2 + \theta_3 I_3)S\sigma(t) - \alpha_0 E_0 \quad (9)$$

$$E_1' = \alpha_0 E_0 - \alpha_1 E_1 \quad (10)$$

$$I_0' = \pi \alpha_1 E_1 - \gamma_0 I_0 \quad (11)$$

$$I_1' = (1 - \pi) \alpha_1 E_1 - (\gamma_1 + \rho_1) I_1 \quad (12)$$

$$I_2' = \rho_1 I_1 - (\gamma_2 + \rho_2) I_2 \quad (13)$$

$$I_3' = \rho_2 I_2 - (\gamma_3 + \delta) I_3 \quad (14)$$

$$R' = \gamma_0 I_0 + \gamma_1 I_1 + \gamma_2 I_2 + \gamma_3 I_3 \quad (15)$$

$$D' = \delta I_3 \quad (16)$$

120 where

$$\alpha_1 = \frac{1}{\beta_1} \quad \beta_1 : \text{Length of infectious phase of incubation period}$$

$$\alpha_0 = (\beta - \beta_1)^{-1} \quad \beta : \text{Average incubation period in days}$$

$$\gamma_0 = \frac{1}{\mu} \quad \mu : \text{Duration of asymptomatic infection}$$

$$R_0 = N \left[\frac{\theta_E}{\alpha_1} + \pi \frac{\theta_0}{\gamma_0} + (1 - \pi) \frac{1}{(\gamma_1 + \rho_1)} \left(\theta_1 + \frac{\rho_1}{(\gamma_2 + \rho_2)} \left(\theta_2 + \theta_3 \frac{\rho_2}{(\delta + \rho_3)} \right) \right) \right]$$

R_0 : Basic reproductive ratio

121 **Table 2: Transmission rates for COVID-19**

| Quantity | Value |
|---------------------|----------|
| θ_0 | 0.5/day |
| θ_1 | 0.27/day |
| θ_2 | 0.1/day |
| θ_3 | 0.1/day |
| θ_E | 0.5/day |
| π | 30% |
| μ | 6 days |
| R_0 | 3.2 |
| r | 0.17/day |
| $(\beta - \beta_1)$ | 2 days |

122
123 We considered the impact of intervention and control measures on the spread of COVID-19 with
124 a 30% reduction in transmission from mild cases. (12–14).

125 Given the intensity of the COVID-19 pandemic, where the most developed countries are falling
126 short in allocating appropriate medical facilities to all COVID-19 patients, an under-developed
127 country such as Pakistan has to be very cautious and concerned about optimizing its almost non-
128 existent healthcare facilities relative to its population size. In this regard, it becomes important to
129 analyze the health care capacity along with the COVID-19 estimates and predictions. The
130 analysis is based on the indicators such as hospital beds (per capita), ICU beds (per capita) and

131 ventilators taking into account the effect of intervention to assess the shortfall of resources
132 (Table 3)

133 **Table 3: Hospital capacity indicators**

| Quantity | Total | Per capita | Source |
|---------------|---------------------|------------|-----------------------------------------------------|
| Hospital beds | 132227 ^a | 0.60 | (Pakistan Bureau of Statistics, 2018) |
| Occupancy | 80% | | (Adam T et al, 2003) |
| ICU beds | 3142 | 0.01 | (Phua J et al, 2020) |
| Occupancy | 80% | | (Adam T et al, 2003) |
| Ventilators | 3800 | 0.02 | (Pakistan Institute of Development Economics, 2020) |

134 Results

135 Predicted COVID-19 cases of Pakistan by clinical outcome

136 Figure 1 (Fig 1: Predicted COVID-19 cases of Pakistan by clinical outcome) shows the
137 progression of the epidemic in Pakistan, displaying the changes in the expected number of
138 individuals who are susceptible, exposed, infected and removed as per the modified SEIR model.
139 As the infected cases first experience an asymptomatic phase (incubation period) followed by an
140 infected phase that varies in intensity, the Infected individuals have been further categorized into
141 infected-asymptomatic; infected-mild (I_1); infected-severe (I_2) and infected-critical (I_3) whereas
142 the Removed category has been sub-divided into recovered and dead depending upon the end
143 result of the infection. Using the $R_0 = 3.2$ and $r = 0.17$, it is predicted that the inflection
144 point/peak is expected to fall on the 117th day (21st June, 2020) in Pakistan. The rate at which the
145 infection would be spreading according to this model is reflected by T_2 , which would be 4.1
146 days. The total susceptible population would be 43.24 million, exposed individuals would be
147 almost 32 million, asymptomatic cases would be 13.13 million, mildly infected 30.64 million,
148 severely infected slightly more than 6 million and critical cases would be around 967,000 in
149 number. By that time, almost 760,000 fatalities of infected critical would have taken place.

150 Reduction in predicted COVID-19 infected cases of Pakistan after intervention

151 Figure 2 (Fig 2: Reduction in predicted COVID-19 infected cases of Pakistan after intervention)
152 shows the changes in the expected numbers of individuals who are symptomatic irrespective of

153 the severity of the infection with and without an intervention being implemented to control the
154 spread of the infection. With the intervention in place, the numbers of symptomatic infected
155 individuals ($I_1+I_2+I_3$) are expected to be almost 20 million while without intervention; this
156 number rises to a maximum of almost 38 million at the peak of the epidemic. Note the change in
157 R_0 as it moves from 3.174 without the intervention to a value of 2.8338 with any intervention.
158 Also noteworthy is the change in doubling time, which increases to 5 days upon implementation
159 of intervention instead of 4 days without intervention depicting the accelerated spread without
160 any control measures in place.

161 **Reduction in predicted COVID-19 deaths of Pakistan after intervention**

162 Almost 5 million deaths could be expected without intervention keeping the Case Fatality Rate
163 (CFR) of Iran of 3.6 as the standard, which can be reduced to 4.39 million deaths if interventions
164 are being implemented to control the spread (Fig 3: Reduction in predicted COVID-19 deaths of
165 Pakistan after intervention).

166 **COVID-19 cases versus healthcare capacity of hospital beds in Pakistan**

167 Figure 4 (Fig 4: COVID-19 cases versus healthcare capacity of hospital beds in Pakistan) shows
168 the number of COVID 19 infections in comparison with the healthcare capacity of Pakistan. If
169 we can flatten the curve to a level below the dashed grey line, the healthcare system will be
170 capable of managing the cases with ideal healthcare facilities, the grey line representing the
171 healthcare capacity of Pakistan.

172 More than seven million individuals with critical and severe infections would need
173 hospitalization while hospital beds are available for only 26,500 individuals at present.

174 **COVID-19 cases vs healthcare capacity of ICU beds in Pakistan**

175 More than 1 million patients would need ventilation and intensive care and considering the
176 number of ICU beds available, the current available capacity of ICUs is around 0.01 per capita to
177 cater to the needs of one million patients (Fig. 5: COVID-19 cases vs healthcare capacity of ICU
178 beds in Pakistan).

179 **COVID-19 cases vs healthcare capacity of ventilators in Pakistan**

180 More than 1 million patients would need ventilators along with intensive care and considering
181 the current number of ventilators, only 0.02 per capita would be available (Fig 6: COVID-19
182 cases vs healthcare capacity of ventilators in Pakistan).

183 Discussion

184 Our results show how the susceptible cases would increase over time along with expected
185 number of deaths. These figures look a bit exaggerated when compared to the reported data. But
186 they have similar results and trends for this pandemic done for other countries currently
187 experiencing some of the highest numbers of cases and deaths. As the recovered increase, the
188 susceptible population goes down. The country's peak is however yet to be seen(15–17). Our
189 results of with and without intervention show a small impact of an intervention (nearly 10
190 million less cases) as compared to number of expected cases, in reducing transmission of
191 diseases with “ r ” = 0.17 dropping to r = 0.15 with intervention. This small reduction with a
192 single intervention has been well documented (18). Timely interventions could reduce the
193 expected cases almost by half, and the expected load on the health system's capacity, which is
194 quite limited. This could be possible only by introducing appropriate interventions for reducing
195 community transmission by social distancing, identifying cases and contacts by sufficient
196 number of tests for isolating the contacts/suspected cases in quarantines and treatment of cases
197 under suitable infection control conditions taken care of by healthcare personnel protected by
198 personal protective equipment (PPE). The severe infected cases would need hospitalization while
199 those in critical condition would require ventilators and care in Intensive Care Units (ICUs)(19–
200 23). Flattening of the curve and bringing it down with recommended interventions could not only
201 compensate for the limited capacity of the ICUs's capacity and need for ventilators, it would also
202 improve the efficiency and preparedness of the system in saving lives(18,24,25).

203 Conclusion and Recommendations

204 We conclude that Pakistan's COVID 19 outbreak is yet to see its see its peak probably towards
205 the third week of June 2020. The cases and admissions in emergency and critical care would
206 compromise the working of the health system. Timely implementation of the prudent
207 interventions would minimize the morbidity and mortality due to the pandemic and would
208 support the weak health system in responding to the outbreak. Pakistan need to invest in the
209 resilient health system and robust pandemic preparedness in place to address control measures
210 for a pandemic as large and devastating as COVID 19.

211 **Limitations and strengths**

212 Our results are based on assumptions and subsequent predictions based on modeling. These may
213 not be accurate. The mathematical models can guide and inform of a magnitude of disease or
214 event. It is imperative that the policy makers may make their own informed judgement in the
215 best interest of providing timely preventive and curative healthcare. The study's strength lies in
216 its methodical approach, which is the best available SEIR model available to date for predicting
217 the course of a pandemic.

218 **Acknowledgements**

219 We acknowledge work done and published by different renowned scientists, whom we have
220 cited in our article. Without this knowledge base, we would not have been able to make these
221 scientific predictions.

222 **Conflict of interest**

223 We declare that we do not have any conflict of interest whatsoever in conducting this analysis
224 and drafting the manuscript.

225 Authors' contribution

226 Ejaz Ahmad Khan conceived the idea, design of the study and helped in analysis, and finalized
227 the manuscript.

228 Maida Umar conducted the analysis wrote the results and helped in writing methods.

229 Maryam Khalid wrote the method section.

230 **References**

- 231 1. Velavan TP, Meyer CG. The COVID-19 epidemic. *Tropical Medicine and International*
232 *Health*. 2020.
- 233 2. Sun P, Lu X, Xu C, Sun W, Pan B. Understanding of COVID-19 based on current
234 evidence. *Journal of Medical Virology*. 2020.
- 235 3. Ali I. Pakistan confirms first two cases of coronavirus, govt says “no need to panic.” *Daily*
236 *Dawn Pakistan* [Internet]. 2020 [cited 2020 May 4]; Available from:
237 <https://www.dawn.com/news/1536792>
- 238 4. <http://www.covid.gov.pk/stats/pakistan>. Accessed on May 16, 2020.
- 239 5. Eastman B, Meaney C, Przedborski M, Kohandel M. Mathematical modeling of COVID-
240 19 containment strategies with considerations for limited medical resources. *medRxiv*.
241 2020;
- 242 6. Turk PJ, Chou S-H, Kowalkowski MA, Palmer PP, Priem JS, Spencer MD, et al.
243 Modeling COVID-19 latent prevalence to assess a public health intervention at a state and
244 regional scale. *medRxiv*. 2020;
- 245 7. Costa PJ. *Applied Mathematics for the Analysis of Biomedical Data*. Applied
246 *Mathematics for the Analysis of Biomedical Data*. 2017.
- 247 8. Ivorra B, Ferrández MR, Vela-Pérez M, Ramos AM. Mathematical modeling of the spread
248 of the coronavirus disease 2019 (COVID-19) taking into account the undetected
249 infections. The case of China. *Commun Nonlinear Sci Numer Simul*. 2020;
- 250 9. Chen X, Zheng F, Qing Y, Ding S, Yang D, Lei C, et al. Epidemiological and clinical
251 features of 291 cases with coronavirus disease 2019 in areas adjacent to Hubei, China: a
252 double-center observational study. *medRxiv*. 2020 Mar 6;2020.03.03.20030353.
- 253 10. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation and
254 Treatment Coronavirus (COVID-19). *StatPearls*. 2020.
- 255 11. Day M. Covid-19: four fifths of cases are asymptomatic, China figures indicate. *BMJ*.
256 2020 Apr 2;369:m1375.
- 257 12. Fang Y, Nie Y, Penny M. Transmission dynamics of the COVID-19 outbreak and
258 effectiveness of government interventions: A data-driven analysis. *J Med Virol*. 2020;
- 259 13. Koo JR, Cook AR, Park M, Sun Y, Sun H, Lim JT, et al. Interventions to mitigate early
260 spread of SARS-CoV-2 in Singapore: a modelling study. *Lancet Infect Dis*. 2020;

- 261 14. Prem K, Liu Y, Russell TW, Kucharski AJ, Eggo RM, Davies N, et al. The effect of
262 control strategies to reduce social mixing on outcomes of the COVID-19 epidemic in
263 Wuhan, China: a modelling study. *Lancet Public Heal.* 2020;0(0).
- 264 15. Pal D, Ghosh D, Santra PK, Mahapatra GS. Mathematical Analysis of a COVID-19
265 Epidemic Model by using Data Driven Epidemiological Parameters of Diseases Spread in
266 India. *medRxiv.* 2020;
- 267 16. Choi SC, Ki M. Estimating the reproductive number and the outbreak size of Novel
268 Coronavirus disease (COVID-19) using mathematical model in Republic of Korea.
269 *Epidemiol Health.* 2020;
- 270 17. Peirlinck M, Linka K, Sahli Costabal F, Kuhl E. Outbreak dynamics of COVID-19 in
271 China and the United States. *Biomech Model Mechanobiol.* 2020;
- 272 18. Ferguson NM, Laydon D, Nedjati-Gilani G, Imai N, Ainslie K, Baguelin M, et al. Impact
273 of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare
274 demand. 2020;(March):20.
- 275 19. Teslya A, Pham TM, Godijk NG, Kretzschmar ME, Bootsma MCJ, Rozhnova G. Impact
276 of Self-Imposed Prevention Measures and Short-Term Government Intervention on
277 Mitigating and Delaying a COVID-19 Epidemic. *SSRN Electron J.* 2020;
- 278 20. Barrett K, Khan YA, Mac S, Ximenes R, Naimark DM, Sander B. Potential Magnitude of
279 COVID-19-Induced Healthcare Resource Depletion in Ontario, Canada. *SSRN Electron J.*
280 2020;
- 281 21. Weissman GE, Crane-Droesch A, Chivers C, Luong T, Hanish A, Levy MZ, et al. Locally
282 Informed Simulation to Predict Hospital Capacity Needs During the COVID-19
283 Pandemic. *Ann Intern Med.* 2020;
- 284 22. Giannakeas V, Bhatia D, Warkentin MT, Bogoch II, Stall NM. Estimating the Maximum
285 Capacity of COVID-19 Cases Manageable per Day Given a Health Care System's
286 Constrained Resources. *Ann Intern Med.* 2020;
- 287 23. De Brouwer E, Raimondi D, Moreau Y. Modeling the COVID-19 outbreaks and the
288 effectiveness of the containment measures adopted across countries. *medRxiv.* 2020;
- 289 24. Armocida B, Formenti B, Ussai S, Palestra F, Missoni E. The Italian health system and the
290 COVID-19 challenge. *The Lancet Public Health.* 2020.
- 291 25. Mandal S, Bhatnagar T, Arinaminpathy N, Agarwal A, Chowdhury A, Murhekar M, et al.

- 292 Prudent public health intervention strategies to control the coronavirus disease 2019
293 transmission in India: A mathematical model-based approach. *Indian J Med Res.* 2020;
- 294 1. Velavan TP, Meyer CG. The COVID-19 epidemic. *Tropical Medicine and International*
295 *Health.* 2020.
- 296 2. Sun P, Lu X, Xu C, Sun W, Pan B. Understanding of COVID-19 based on current
297 evidence. *Journal of Medical Virology.* 2020.
- 298 3. Ali I. Pakistan confirms first two cases of coronavirus, govt says “no need to panic.” *Daily*
299 *Dawn Pakistan* [Internet]. 2020 [cited 2020 May 4]; Available from:
300 <https://www.dawn.com/news/1536792>
- 301 4. No Title. p. <http://www.covid.gov.pk/stats/pakistan>.
- 302 5. Eastman B, Meaney C, Przedborski M, Kohandel M. Mathematical modeling of COVID-
303 19 containment strategies with considerations for limited medical resources. *medRxiv.*
304 2020;
- 305 6. Turk PJ, Chou S-H, Kowalkowski MA, Palmer PP, Priem JS, Spencer MD, et al.
306 Modeling COVID-19 latent prevalence to assess a public health intervention at a state and
307 regional scale. *medRxiv.* 2020;
- 308 7. Costa PJ. *Applied Mathematics for the Analysis of Biomedical Data.* Applied
309 *Mathematics for the Analysis of Biomedical Data.* 2017.
- 310 8. Ivorra B, Ferrández MR, Vela-Pérez M, Ramos AM. Mathematical modeling of the spread
311 of the coronavirus disease 2019 (COVID-19) taking into account the undetected
312 infections. The case of China. *Commun Nonlinear Sci Numer Simul.* 2020;
- 313 9. Chen X, Zheng F, Qing Y, Ding S, Yang D, Lei C, et al. Epidemiological and clinical
314 features of 291 cases with coronavirus disease 2019 in areas adjacent to Hubei, China: a
315 double-center observational study. *medRxiv.* 2020 Mar 6;2020.03.03.20030353.
- 316 10. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation and
317 Treatment Coronavirus (COVID-19). *StatPearls.* 2020.
- 318 11. Day M. Covid-19: four fifths of cases are asymptomatic, China figures indicate. *BMJ.*
319 2020 Apr 2;369:m1375.
- 320 12. Fang Y, Nie Y, Penny M. Transmission dynamics of the COVID-19 outbreak and
321 effectiveness of government interventions: A data-driven analysis. *J Med Virol.* 2020;
- 322 13. Koo JR, Cook AR, Park M, Sun Y, Sun H, Lim JT, et al. Interventions to mitigate early

- 323 spread of SARS-CoV-2 in Singapore: a modelling study. *Lancet Infect Dis.* 2020;
- 324 14. Prem K, Liu Y, Russell TW, Kucharski AJ, Eggo RM, Davies N, et al. The effect of
325 control strategies to reduce social mixing on outcomes of the COVID-19 epidemic in
326 Wuhan, China: a modelling study. *Lancet Public Heal.* 2020;0(0).
- 327 15. Pal D, Ghosh D, Santra PK, Mahapatra GS. Mathematical Analysis of a COVID-19
328 Epidemic Model by using Data Driven Epidemiological Parameters of Diseases Spread in
329 India. *medRxiv.* 2020;
- 330 16. Choi SC, Ki M. Estimating the reproductive number and the outbreak size of Novel
331 Coronavirus disease (COVID-19) using mathematical model in Republic of Korea.
332 *Epidemiol Health.* 2020;
- 333 17. Peirlinck M, Linka K, Sahli Costabal F, Kuhl E. Outbreak dynamics of COVID-19 in
334 China and the United States. *Biomech Model Mechanobiol.* 2020;
- 335 18. Ferguson NM, Laydon D, Nedjati-Gilani G, Imai N, Ainslie K, Baguelin M, et al. Impact
336 of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare
337 demand. 2020;(March):20.
- 338 19. Teslya A, Pham TM, Godijk NG, Kretzschmar ME, Bootsma MCJ, Rozhnova G. Impact
339 of Self-Imposed Prevention Measures and Short-Term Government Intervention on
340 Mitigating and Delaying a COVID-19 Epidemic. *SSRN Electron J.* 2020;
- 341 20. Barrett K, Khan YA, Mac S, Ximenes R, Naimark DM, Sander B. Potential Magnitude of
342 COVID-19-Induced Healthcare Resource Depletion in Ontario, Canada. *SSRN Electron J.*
343 2020;
- 344 21. Weissman GE, Crane-Droesch A, Chivers C, Luong T, Hanish A, Levy MZ, et al. Locally
345 Informed Simulation to Predict Hospital Capacity Needs During the COVID-19
346 Pandemic. *Ann Intern Med.* 2020;
- 347 22. Giannakeas V, Bhatia D, Warkentin MT, Bogoch II, Stall NM. Estimating the Maximum
348 Capacity of COVID-19 Cases Manageable per Day Given a Health Care System's
349 Constrained Resources. *Ann Intern Med.* 2020;
- 350 23. De Brouwer E, Raimondi D, Moreau Y. Modeling the COVID-19 outbreaks and the
351 effectiveness of the containment measures adopted across countries. *medRxiv.* 2020;
- 352 24. Armocida B, Formenti B, Ussai S, Palestra F, Missoni E. The Italian health system and the
353 COVID-19 challenge. *The Lancet Public Health.* 2020.

- 354 25. Mandal S, Bhatnagar T, Arinaminpathy N, Agarwal A, Chowdhury A, Murhekar M, et al.
355 Prudent public health intervention strategies to control the coronavirus disease 2019
356 transmission in India: A mathematical model-based approach. *Indian J Med Res.* 2020;
357
358











